Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?
There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data s...
Main Authors: | Jacob W. Bruinius, Karl J. Dykema, Sabrina L. Noyes, Bin Tean Teh, Brian R. Lane |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Case Reports in Urology |
Online Access: | http://dx.doi.org/10.1155/2019/2479823 |
Similar Items
-
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients.
by: Mario Scartozzi, et al.
Published: (2012-01-01) -
Vascular endothelial growth factor (VEGF) and prostate pathology
by: Francisco Botelho, et al.
Published: (2010-08-01) -
VEGF Carrying Coatings for Enhanced Vascular Graft Endothelialization
by: Schaubhut, Frank
Published: (2010) -
Angiogenesis mediated by vascular endothelial growth factor (VEGF)
by: Wang, Wenying
Published: (2004) -
The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling.
by: Marianne O Stefanini, et al.
Published: (2009-12-01)